New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Psoriasis affects your body’s immune system, causing it to produce too many skin cells. Those extra cells build up and create a flaky rash that may appear red, purple, ashen gray, or brown ...

Plaque psoriasis-often mistaken for dry skin or eczema-isn't always easy to manage and usually causes discomfort. Recently, the actress and TV personality opened up to First For Women about her ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

It wasn’t until two years after her symptoms began that she finally found a dermatologist who identified her “itchy spots” as evidence of plaque psoriasis, a chronic autoimmune disorder that ...

Please provide your email address to receive an email when new articles are posted on . Overall, 84.1% and 70.5% of patients treated with icotrokinra achieved IGA 0 or 1 and PASI 90, respectively ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ...

On Oct. 1, La La Anthony took to Instagram to share her personal struggle with plaque psoriasis ... This is particularly significant for Black women who often embrace protective hairstyles ...